Performance of 5-domain rhinology-focused symptom score with dupilumab in chronic rhinosinusitis with nasal polyps.

Competing Interests: Disclosures Dr Kuo reports personal fees from AstraZeneca, personal fees from Chiesi, and nonfinancial support from GlaxoSmithKline outside the submitted work. Dr Chan reports personal fees (talks) and support attending the European Respiratory Society (ERS) from AstraZeneca, personal fees (consulting) from Vitalograph, and personal fees (talks) from Thorasys. Dr Lipworth reports nonfinancial support (equipment) from GlaxoSmithKline; grants, personal fees (consulting, talks, and advisory board), and other support (attending American Thoracic Society and ERS) from AstraZeneca; personal fees (talks and consulting) from Sanofi; personal fees (consulting, talks and advisory board) from Circassia; grants, personal fees (consulting, talks, and advisory board), and other support (attending ERS) from Teva; personal fees (talks and consulting), grants, and other support (attending ERS and British Thoracic Society) from Chiesi; personal fees (consulting) from Lupin; personal fees (consulting) from Glenmark; personal fees (consulting) from Dr Reddy; personal fees (consulting) from Sandoz; grants, personal fees (consulting, talks, and advisory board), and other support (attending British Thoracic Society) from Boehringer Ingelheim; and grants and personal fees (advisory board and talks) from Mylan outside of the submitted work. Moreover, Dr Lipworth's son is currently an employee of AstraZeneca. Dr Stewart has no conflicts of interest to report.